Crossmark

The FKBPL-based therapeutic peptide, AD-01, protects the endothelium from hypoxia-induced damage by stabilising hypoxia inducible factor-α and inflammation

Crossref DOI link: https://doi.org/10.1186/s12967-025-06118-w

Published Online: 2025-03-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ghorbanpour, Sahar

Cartland, Siân Peta

Chen, Hao

Seth, Sanchit

Ecker, Rupert C.

Richards, Claire

Aksentijevic, Dunja

Padula, Matthew P.

Cole, Louise

Warkiani, Majid Ebrahimi

Kavurma, Mary Meltem

McClements, Lana https://orcid.org/0000-0002-4911-1014
Funding

Funding for this research was provided by:

National Heart Foundation of Australia (106628)
License Information

Text and Data Mining valid from 2025-03-11

Version of Record valid from 2025-03-11
More Information

Article History

Received: 2 August 2024

Accepted: 8 January 2025

First Online: 11 March 2025

Declarations

:

: All procedures were approved by the University of New South Wales Animal Care and Ethics Committee (Sydney, Australia; 07/26B), and conformed to the NIH Guide for the Care and Use of Laboratory Animals.

: The manuscript does not contain data or images from an individual person and is therefore not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below